Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes
More topics under "A61K - Preparations for medical, dental, or toilet purposes" (2,585,043)
A61K 101 - Radioactive non-metals (526)
A61K 103 - Radioactive metals (481)
A61K 125 - Containing or obtained from roots, bulbs, tubers, corms or rhizomes (2,645)
A61K 127 - Containing or obtained from leaves (1,806)
A61K 129 - Containing or obtained from bark (325)
A61K 131 - Containing or obtained from seeds, nuts, fruits or grains (1,932)
A61K 133 - Containing or obtained from flowers or blossoms (665)
A61K 135 - Containing or obtained from stems, stalks, branches, twigs or shoots (756)
A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
A61K 33 - Medicinal preparations containing inorganic active ingredients (56,213)
A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838)
A61K 36 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines (179,316)
A61K 38 - Medicinal preparations containing peptides (316,240)
A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
A61K 41 - Medicinal preparations obtained by treating materials with wave energy or particle radiation (9,445)
A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
A61K 49 - Preparations for testing in vivo (35,376)
A61K 50 - Electrically conductive preparations for use in therapy or testing in vivo, e.g. conductive adhesives or gels to be used with electrodes for electrocardiography (ecg) or for transcutaneous drug administration (62)
A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
A61K 6 - Preparations for dentistry (18,259)
A61K 8 - Cosmetics or similar toilet preparations (170,551)
A61K 9 - Medicinal preparations characterised by special physical form (299,044)
Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449)
05/2005
05/18/2005CN1617736A Vaccine and method for treatment of motor neurone diseases
05/18/2005CN1617723A Use of a compound in the treatment of sleep disorders and the like, in providing refreshedness on waking and a method for the treatment of grogginess therewith
05/18/2005CN1617720A Use of pramipexole to treat amyotrophic lateral sclerosis
05/18/2005CN1617712A Pharmaceutical nanoparticulate composition of a tachykinin receptor antagonist
05/18/2005CN1615833A N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them
05/18/2005CN1202108C Spiro compounds, preparing method and intermediate
05/18/2005CN1202087C Derivatives of acyl-piperazinil-pyrimidins, preparation thereof and application as medicaments
05/18/2005CN1201740C Intermittent claudication therapeutic drugs comprising phyrroloazepines
05/18/2005CN1201722C Effect improved anhidrotic emulsion containing fine aluminum and zirconium powders, and preparing method thereof
05/18/2005CN1201717C Composite for oxidation-dyeing keratin fibre and its dyeing method
05/17/2005US6894064 Benzothiophenes, formulations containing same, and methods
05/17/2005US6894058 Administering statin drug
05/17/2005US6894041 Oxazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes
05/17/2005US6894032 Or salt thereof
05/17/2005CA2350061C New controlled release bead, a method of producing the same and multiple unit formulation comprising it
05/17/2005CA2119434C Compositions containing sunscreens
05/12/2005WO2005043123A2 System and apparatus for body fluid analysis using surface-textured optical materials
05/12/2005WO2005042795A2 Plasma polymerization of atomically modified surfaces
05/12/2005WO2005041904A2 Inhibitors of coronavirus protease and methods of use thereof
05/12/2005WO2005041903A2 Methods and reagents for diagnosis and treatment of diabetes
05/12/2005WO2005041902A2 Anion-binding polymers and uses thereof
05/12/2005WO2005041901A2 Therapeutics using somatostatin agonists
05/12/2005WO2005041900A2 Polyamine polymers
05/12/2005WO2005041899A2 Orally available sphingosine 1-phosphate receptor agonists and antagonists
05/12/2005WO2005041898A2 Blood substitutes
05/12/2005WO2005041897A2 Reconstitutable microsphere compositions useful as ultrasonic contrast agents
05/12/2005WO2005041896A2 Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction or stroke
05/12/2005WO2005041895A2 Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on their albumin binding properties
05/12/2005WO2005041894A2 Compositions and methods for treating, preventing, reversing and inhibiting pain
05/12/2005WO2005041893A2 Detection of acute myocardial infarction biomarkers
05/12/2005WO2005041892A2 Purine receptor inhibition as a therapeutic strategy in spinal cord and brain
05/12/2005WO2005041891A2 Neutrophil activation by immune response modifier compounds
05/12/2005WO2005041888A2 Pyrimidin-4-one compounds, compositions and methods
05/12/2005WO2005041887A2 Pigment epithelium-derived factor, novel biological activity and methods of use
05/12/2005WO2005041886A2 Methods for generating or increasing revenues related to pain inhibitor commerce
05/12/2005WO2005041885A2 Compositions and methods for treating, preventing, reversing and inhibiting pain
05/12/2005WO2005041884A2 Polymer-based microstructures
05/12/2005WO2005041883A2 Reduction of unintended use of transdermal devices
05/12/2005WO2005041882A2 Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs
05/12/2005WO2005041881A2 Taxoid-fatty acid conjugates and pharmaceutical compositions thereof
05/12/2005WO2005041880A2 RhPV AS A MODEL FOR HPV-INDUCED CANCERS
05/12/2005WO2005041879A2 COMBINATIONS COMPRISING AN Hsp90 INHIBITOR AND A PHOPHODIESTERASE INHIBITOR FOR TREATING OR PREVENTING NEOPLASIA
05/12/2005WO2005041878A2 Compositions and methods for increasing hdl and hdl-2b levels
05/12/2005WO2005041877A2 Method of inhibiting rejection following organ transplantation
05/12/2005WO2005041876A2 Spill resistant formulations containing clays
05/12/2005WO2005041875A2 Dopamine-, norepinephrine- and serotonin- transporter- selective heterocyclic compounds and their therapeutic applications
05/12/2005WO2005041874A2 Method and antisense composition for selective inhibition of hiv infection in hematopoietic cells
05/12/2005WO2005041873A2 Formulation of exendin-4
05/12/2005WO2005041872A2 Use of peroxisome proliferator-activated receptor gamma (pparϝ) and/or retinoic acid receptor (rxr) agonists to inhibit platelet functions
05/12/2005WO2005041870A2 Composition and method for the treatment of eye disease
05/12/2005WO2005041869A2 Process for co-spray drying agents with dry silicified mcc
05/12/2005WO2005041868A2 Epidermal growth factor receptor modulation protects normal tissue
05/12/2005WO2005041867A2 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3’(1h-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrozol-3-one choline
05/12/2005WO2005041866A2 Pharmaceutical formulations, methods and dosing regimens for the treatment and prevention of acute coronary syndromes
05/12/2005WO2005041865A2 Compounds and method for treating cancer
05/12/2005WO2005041864A2 Combination of cyclooxygenase-2 inhibitor and phosphodiesterase 4 inhibitor and method
05/12/2005WO2005041863A2 Method for interconnecting longitudinal members extending along a spinal column
05/12/2005WO2005041862A2 Neutralizing antibodies against extracellular hexosaminidase for treatment of arthritis
05/12/2005WO2005041861A2 Anhydrous silver dihydrogen citrate compositions
05/12/2005WO2005041858A2 Mucin production inhibitor
05/12/2005WO2005041857A2 Bone morphogenetic protein (bmp) 2a and uses thereof
05/12/2005WO2005041856A2 Use of 2-thia-dibenzo[e, h]azulenes for the treatment and prevention of central nervous system diseases and disorders
05/12/2005WO2005041854A2 Composition for the cosmetic treatment of age-related dermatological symptoms
05/12/2005WO2005041853A2 Antibacterial and/or antiprotozoal nitroimidazole derivative compounds with urease inhibitor activity, process for preparing these compounds and use in pharmaceutical compositions and medicines.
05/12/2005WO2005041852A2 Keratin gel and the types 2, 4 and 6 of collagens of frog protein
05/12/2005WO2005032488A3 2,4-dioxo-3-quinazolinylaryl sulfonylureas
05/12/2005WO2005030131A3 Bis-quinazoline compounds for the treatment of bacterial infections
05/12/2005WO2005026192A3 Hpv cd8+ t-cell epitopes
05/12/2005WO2005021777A3 Uses of spatial configuration to modulate protein function
05/12/2005WO2005018578A3 Method of treating cancer with hdac inhibitors
05/12/2005WO2005018531A3 Pharmaceutical compositions, azo-heterocyclic compounds and method for the production and use thereof
05/12/2005WO2005013911A3 Protective and therapeutic uses for tocotrienols
05/12/2005WO2005011573A3 Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders
05/12/2005WO2005009367A3 Treatment of diseases with kinase inhibitors
05/12/2005WO2005009343A3 A1 adenosine receptor antogonists
05/12/2005WO2005007075B1 Adaptive resynchronization therapy system
05/12/2005WO2005007072A3 Methods and pharmaceutical compositions for healing wounds
05/12/2005WO2005004804A3 Compositions and methods for selective dissolution of nascent intravascular blood clots
05/12/2005WO2005000231A3 Il-8 receptor antagonists
05/12/2005WO2004110375A3 Combination therapy for the treatment of diabetes
05/12/2005WO2004110370A3 Etiologic agnet for sow infertility syndrome
05/12/2005WO2004108091A3 Antimicrobial flush solutions
05/12/2005WO2004105682A3 Carbostyril derivatives and mood stabilizers for treating mood disorders
05/12/2005WO2004103311A3 Antibiotic composition
05/12/2005WO2004103270A3 Compounds and methods for treatment of thrombosis
05/12/2005WO2004093829A8 (-)1-(4-sulfamylaryl)-3-substituted-5-heteroaryl-2 pyrazolines as inhibitors of cyclooxygenase-2
05/12/2005WO2004091509A3 Interlinked culture chambers for biologicals
05/12/2005WO2004089312A3 New piperidinylamino-thieno[2,3-d] pyrimidine compounds
05/12/2005WO2004087061B1 Tubulin binding agents and corresponding prodrug constructs
05/12/2005WO2004084828A3 Keratinocyte-fibrocyte concomitant grafting for wound healing
05/12/2005WO2004082639A3 Detecting coronary artery disease with bnp during stress testing
05/12/2005WO2004078125A3 Aerosol antiperspirant with polyamide
05/12/2005WO2004073628A3 Novel compounds
05/12/2005WO2004071391A3 Imidazopyridines containing combinations and their use in treating gastrointestinal inflammatory disorders
05/12/2005WO2004064778A3 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
05/12/2005WO2004064710A3 Applications of substances binding to gstm for the diagnosis and treatment of cystic carcinomas
05/12/2005WO2004017918A8 Method of preparing dry powder inhalation compositions
05/12/2005US20050102708 Rodent model generated by continuous infusion of a Fe2+, A beta 42 and buthionine sulfoximine for use as diagnostic and therapeutic screening tool in detection and treatment of alzheimer's disease
05/12/2005US20050101721 Polymeric interpenetrated network carrier and serial polymerization involving a crosslinked polymer network
05/12/2005US20050101663 Synthetic lactone formulations and method of use
1 ... 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 ... 295